Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV20 and PCV21 for Cross-protection Against Novel Pneumococcal Serotypes
NCT07135453Phase 4Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jul 2026
- Primary completion
- Mar 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Prevnar 20, PCV21 in pneumococcal disease, sponsored by University of Alabama at Birmingham. Started Jul 2026; status: recruiting.
02
Drugs
Prevnar 20PCV21
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07135453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07135453.